$LLY Company News Drug-maker earnings come in ahead of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2013 at 4:32 PM

$LLY Company News

Drug-maker earnings come in ahead of views, but stocks aren't rewarded 10:45 a.m. Oct. 23, 2013 - Russ Britt
Stock futures retreat; Cat misses on earnings 7:42 a.m. Oct. 23, 2013 - William L. Watts
Eli Lilly net profit down 9.3%, revenue rises 6:03 a.m. Oct. 23, 2013 - MarketWatch.com
Eli Lilly 3Q adj. EPS FactSet estimate was $1.04 5:39 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q revenue up 6% to $5.77 billion 5:38 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q net income down 9% to $1.20 billion 5:37 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q adj. EPS up 41% to $1.11 5:35 a.m. Oct. 23, 2013 - Sara Sjolin
Boeing, AT&T, Caterpillar are stocks to watch 4:31 a.m. Oct. 23, 2013 - Sue Chang
The market in a minute: Playing with volatility 7:42 a.m. Oct. 21, 2013 - The Trading Deck
Eli Lilly downgraded to underperform by Jefferies 8:21 a.m. Oct. 11, 2013 - Ben Eisen
Tesla stuck in reverse, Herbalife loses momentum 3:35 p.m. Oct. 3, 2013 - Sue Chang
Lilly unveils $5 billion share-buyback program 7:02 a.m. Oct. 3, 2013 - MarketWatch.com
J.C. Penney snaps losing streak; Facebook tops $50 3:36 p.m. Sept. 26, 2013 - Sue Chang
3 dividend stocks for worried investors 5:00 a.m. Sept. 9, 2013 - Jeff Reeves
Renaissance Technologies' top dividend picks 3:25 p.m. Aug. 23, 2013 - Insider Monkey
Tuesday’s movers: Airline stocks, Apple 3:32 p.m. Aug. 13, 2013 - Maria LaMagna
U.S. stocks rise with help from Apple Inc. 3:21 p.m. Aug. 13, 2013 - Kate Gibson
Updates, advisories and surprises 5:01 p.m. July 24, 2013 - MarketWatch
Lilly shares up on higher earnings, lower expenses; Elan also rises 11:00 a.m. July 24, 2013 - Russ Britt
Apple, AT&T, Boeing are stocks to watch Wednesday 8:24 a.m. July 24, 2013 - Maria LaMagna

Twitter Cools Off, Loeb’s Stake in Sony, and 3 More Hot Stocks 11:02 a.m. Today - Wall St. Cheat Sheet
UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline 9:17 a.m. Today - benzinga.com
Top Analyst Upgrades and Downgrades: Twitter, Best Buy, Exxon and More 8:01 a.m. Today - 247WallSt.com
Insiders Are Buying Navidea 1:18 p.m. Nov. 10, 2013 - Seeking Alpha
Pfizer And Merck Continue To Battle Declining Revenue 11:49 a.m. Nov. 10, 2013 - Seeking Alpha
Life After Momentum Slows 10:47 a.m. Nov. 9, 2013 - Seeking Alpha
4 Healthcare Sector Dogs Hype 13% To 17% October Upsides; 4% To 7.5% Downsides 7:02 p.m. Nov. 8, 2013 - Seeking Alpha
Multiple Reasons To Buy Incyte 3:25 p.m. Nov. 8, 2013 - Seeking Alpha
Lower-than-Expected Loss at OncoGenex - Analyst Blog 3:20 p.m. Nov. 8, 2013 - Zacks.com
Eli Lilly Goes Down The Hill As Patents Expire 1:46 p.m. Nov. 8, 2013 - Seeking Alpha
3 Huge Healthcare Trends Can Fatten Your Portfolio 4:00 a.m. Nov. 8, 2013 - InvestorPlace.com
Stocks to Sell or Short: The Seven Least Preferred Stocks at UBS 8:28 a.m. Nov. 7, 2013 - 247WallSt.com
China Drags on Western Profits 12:23 a.m. Nov. 6, 2013 - WSJ.com
Prolific Selling - Hussman's High-Impact Moves Mirror Insiders 9:51 a.m. Nov. 5, 2013 - GuruFocus.com
We Like What We're Seeing In Big Pharma 4:15 a.m. Nov. 5, 2013 - Seeking Alpha
Drug Makers Get a Shot in the Arm 7:26 p.m. Nov. 3, 2013 - WSJ.com
Merck - Surprised Weakness In JANUVIA Is Causing Renewed Worries For Investors 2:10 p.m. Oct. 29, 2013 - Seeking Alpha
Eli Lilly Bulls: How Will 2014 Treat You? 10:08 a.m. Oct. 29, 2013 - Seeking Alpha
'Fast Money' Recap: Apple to the Core 5:00 a.m. Oct. 29, 2013 - TheStreet.com
Merck Profit Falls on Lower Sales 1:32 p.m. Oct. 28, 2013 - WSJ.com

Sponsorships, Pricing of Public Offering, and Investor Meetings - Research Report on Lilly, Mallinckrodt, Integra, and NuVasive 8:00 a.m. Today - PR Newswire
ImmunoGen, Inc. Announces Fifth New License Agreement in 2013 6:30 a.m. Today - BusinessWire
Morning Research: Eli Lilly & Co., Bristol-Myers Squibb Co., Allergan Inc., and Endo Health Solutions Inc. 11:27 a.m. Nov. 4, 2013 - PR Newswire
Fitch: Pharmaceutical Cost Cutting Still Includes R&D for Some 11:18 a.m. Nov. 4, 2013 - BusinessWire
Through 2022, Growth in the Neuropathic Pain Drug Market Will be Constrained by the Genericization of Sales-Leading Agents from Eli Lilly/Shionogi, Endo/Grunenthal and Pfizer 9:00 a.m. Nov. 4, 2013 - PR Newswire
Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes 9:00 a.m. Nov. 1, 2013 - PR Newswire
Dividend, Quarterly Report, Recognition, Study Results, and New Drug Application - Research Report on Pfizer, Lilly, Regeneron, Vertex, and GSK 9:00 a.m. Nov. 1, 2013 - PR Newswire
In Russia, the Use of Premium-Priced Novel Agents Will Expand the Acute Coronary Syndrome Market Through 2017 10:00 a.m. Oct. 29, 2013 - PR Newswire
Lessons From Hurricane Sandy: American College of Endocrinology (ACE) Urges Those With Diabetes to Plan Ahead 9:50 a.m. Oct. 29, 2013 - BusinessWire
The Alzheimer's Disease Drug Market Will Triple by 2022, Driven Largely by the Projected Launch of Eli Lilly's Solanezumab 9:00 a.m. Oct. 29, 2013 - PR Newswire
FDA Approves Addition to CIALIS® (tadalafil) Product Label 8:00 a.m. Oct. 25, 2013 - PR Newswire
Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets 5:00 p.m. Oct. 24, 2013 - PR Newswire
Critical Alerts For LinkedIn, MasterCard, News Corp, Eli Lilly, and ASML Holdings Released By InvestorsObserver 9:31 a.m. Oct. 24, 2013 - PR Newswire
Returning Value to Shareholders through Dividends, Strong Financial Results, and Regulatory Approvals - Research Report on Lilly, Illumina, Regeneron, Teva, and Vanda Pharmaceuticals 8:00 a.m. Oct. 24, 2013 - PR Newswire
FDA Grants Lilly's Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer 6:31 a.m. Oct. 23, 2013 - PR Newswire
Lilly Reports Third-Quarter 2013 Results 6:30 a.m. Oct. 23, 2013 - PR Newswire
Jackson Tai Elected to Lilly Board of Directors 10:21 a.m. Oct. 22, 2013 - PR Newswire
Jackson Tai Elected to Lilly Board of Directors 8:00 a.m. Oct. 22, 2013 - PR Newswire
Lilly Declares Fourth-Quarter 2013 Dividend 4:15 p.m. Oct. 21, 2013 - PR Newswire
ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Versatility of Novel Gene Expression and Control Technology 12:30 p.m. Oct. 21, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Advocacy for Hiring Disabled Kidney Patients Gains Steam

Making Jobs Accessible for Kidney Patients Well, things are stirring up on Capitol Hill, and it's high time, if you ask me. The American Association of Kidney Patients (AAKP) is rallying hard for a bipartisan bill that could change the landscape for folks grappling with kidney diseases and disabilities. You’ve got Reps Pete Sessions and Steny Hoyer pushing this American...

First Citizens Surprises with Q3 Gains and Buyback Plan

Unexpected Third Quarter Tailwinds for First Citizens There are days in this trading gig when a bank I'll barely sneeze at hits out of the park. First Citizens BancShares (NASDAQ:FCNCA) pulled off such a feat, wringing out a third-quarter 2026 performance that beat their own benchmarks. They threw $600 million back to shareholders in repurchased stocks while repaying an...

Gentex Shares Tumble Amid Legal Investigation Concerns

Gentex's Financial Outlook Takes a Hit Well, here we are again, catching another corporate hiccup. Gentex Corporation, or as ticker hounds know it, NASDAQ:GNTX, just pulled the rug out from its investors by chopping the top off its 2026 revenue guidance. Dropping to a floor it once considered a ceiling, $2.65 billion is now the most optimistic number they're pitching. No...

A Game-Changer for Pediatric Diabetes: Novo's Awiqli®

Breaking Through the Diabetes Treatment Wall From where I'm sitting, breakthrough approvals like Novo's Awiqli® hit the healthcare landscape with all the subtlety of a freight train. The FDA's green light for Awiqli® as the first once-weekly insulin for kids aged 10 and over with type 2 diabetes is a monumental shift in the treatment paradigm. We're talking about...

Shanghai and Hamburg Celebrate 40 Years of Collaboration

Strengthening the Bond: A Four-Decade Journey With fireworks of diplomacy and cooperation lighting up, Shanghai and Hamburg marked the 40th anniversary of their friendship with an ambition to deepen and broaden ties. These cities, separated by continents but united by their maritime spirit, decided to toast not just the past but also the future. This isn't just some fancy...

Unicoin’s 'RISE IN PINK' Blends Crypto and Charity

The New Face of Charitable Giving: Crypto and Cause Turning the spotlight on how blockchain and altruism can mesh, Unicoin's latest campaign isn’t just your average philanthropic endeavor. With 'RISE IN PINK', they're out to change the game, blending digital assets with a deep human cause—breast cancer awareness and support. Technology Meets Human Cause Imagine...

York Space Systems Class Action: Deadline Approaches

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Astra Security Tackles PHP2Shell Vulnerabilities Head-On

Unlocking the PHP Puzzle Hot off the press, Astra Security's stepping up to the plate with some freebie tools designed to sniff out and stamp out those pesky PHP2Shell vulnerabilities—CVE-2026-109618 and CVE-2026-109619. If you're not familiar, these suckers rate a whopping 9.2 on the CVSS v4.0 scale, and that means they got the potential to let remote code execution...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Lowcountry Kids to Get Free Helmets at Safety Events

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...